Literature DB >> 12401861

A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey.

Serhan Tuglular1, Fatos Yalcinkaya, Saime Paydas, Ayse Oner, Cengiz Utas, Semra Bozfakioglu, Rezzan Ataman, Tekin Akpolat, Ercan Ok, Saniye Sen, Ruhan Düsünsel, Rifki Evrenkaya, Emel Akoglu.   

Abstract

BACKGROUND: Secondary amyloidosis is the most frequent of the various types of systemic amyloidosis, the epidemiology of which is not yet fully known. The aim of our study was to evaluate retrospectively the collective data for the aetiological distribution, clinical findings and approaches to the management of secondary amyloidosis in Turkey.
METHODS: Data from a simple questionnaire addressing aetiology, and demographic and clinical characteristics of patients with biopsy-proven secondary amyloidosis was retrospectively analysed. Eleven nephrology clinics contributed data for this study.
RESULTS: The 11 contributing centres provided a total of 287 cases (102 female, 185 male). The aetiological distribution was as follows: familial Mediterranean fever (FMF) 64%, tuberculosis 10%, bronchiectasis and chronic obstructive lung disease 6%, rheumatoid arthritis 4%, spondylarthropathy 3%, chronic osteomyelitis 2%, miscellaneous 4%, unknown 7%. Oedema accompanied by proteinuria was present in 88% of the cases, hepatomegaly in 17%, and splenomegaly in 11%. The mean systolic and diastolic blood pressures were 115+/-26 and 73+/-15 mmHg respectively. The family history was positive in 16%; 73% of the cases were on colchicine treatment when the questionnaire was administered. Thirty-eight per cent of the cases had progressed to ESRD and were on renal replacement therapy.
CONCLUSIONS: FMF is the leading cause of secondary amyloidosis in Turkey, followed by tuberculosis. Oedema accompanied by proteinuria is the most prominent presenting finding, and hypotension seems to be common among these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401861     DOI: 10.1093/ndt/17.11.2003

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  25 in total

1.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

2.  Relation of gelsolin amyloidosis and periodontal health.

Authors:  Pirjo L Juusela; Rutger G Persson; Anja R Nieminen; Sari M Kiuru-Enari; Veli-Jukka Uitto
Journal:  Clin Oral Investig       Date:  2014-05-23       Impact factor: 3.573

3.  Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis.

Authors:  Birol Balaban; Evren Yasar; Ahmet Ozgul; Kemal Dincer; Tunc Alp Kalyon
Journal:  Rheumatol Int       Date:  2005-02-12       Impact factor: 2.631

4.  Influence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation.

Authors:  Sanket Patke; Ronak Maheshwari; Jeffrey Litt; Saipraveen Srinivasan; J Javier Aguilera; Wilfredo Colón; Ravi S Kane
Journal:  Biochemistry       Date:  2012-03-26       Impact factor: 3.162

5.  Duodenal amyloidosis secondary to ulcerative colitis.

Authors:  Seung Woon Park; Sam Ryong Jee; Ji Hyun Kim; Sang Heon Lee; Jin Won Hwang; Ji Geon Jang; Dong Woo Lee; Sang Yong Seol
Journal:  Intest Res       Date:  2018-01-18

6.  The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis.

Authors:  Soner Senel; Bunyamin Kisacik; Yunus Ugan; Timucin Kasifoglu; Ercan Tunc; Veli Cobankara
Journal:  Clin Rheumatol       Date:  2011-05-28       Impact factor: 2.980

7.  Renal biopsy in the elderly: a single-center experience.

Authors:  Ozlem Harmankaya; Yildiz Okuturlar; Hakan Kocoglu; Hakan Kaptanogullari; Sibel Kocak Yucel; Hanise Ozkan; Didem Acarer; Ezgi Erdogan; Murvet Yilmaz; Mehmet Hursitoglu
Journal:  Int Urol Nephrol       Date:  2015-07-02       Impact factor: 2.370

8.  Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.

Authors:  Serhan Piskinpasa; Hadim Akoglu; Eyup Koc; Fatma Dogru; Ezgi Yenigun Coskun; Didem Turgut; Nihal Ozkayar; Ramazan Ozturk; Ali Riza Odabas; Fatih Dede
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

Review 9.  Currents concepts on the immunopathology of amyloidosis.

Authors:  Anupama Bhat; Carlo Selmi; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

10.  Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis.

Authors:  Jinghua Lu; Yadong Yu; Iowis Zhu; Yifan Cheng; Peter D Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.